The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
September 23, 2021
View Complete Issue         Table of Contents 2019 
Belimumab (Benlysta) for Lupus Nephritis (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Belimumab (Benlysta) for Lupus Nephritis (online only)
September 23, 2021 (Issue: 1634)
The B-lymphocyte stimulator (BLyS)-specific inhibitor belimumab (Benlysta – GSK), which was approved earlier for treatment of active, autoantibody-positive, nonrenal, systemic lupus erythematosus (SLE), has now been approved for use in addition...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Belimumab (Benlysta) for Lupus Nephritis (online only)
Article code: 1634f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.